Tags : Sintilimab injection

Pharma

Innovent and Shenogen Enter into a Collaboration to Evaluate the

Shots: The companies enter into an agreement to evaluate the combination of Innovent’s Tyvyt with Shenogen’s SNG1005 for the patients with advanced cancer  Shenogen has in-licensed SNG1005 and has exclusive rights to develop & commercialize it in Greater China. SNG1005 has completed multiple P-II trials in the US with an approved NMPA’s IND application of […]Read More

Regulatory

Innovent Biologics and Eli Lilly’s Tyvyt (Sintilimab injection) Receives NMPA

Shots: The approval is based on ORIENT-1 study results assessing Tyvyt in patients with 2L+ Hodgkin’s lymphoma The ORIENT-1 study resulted in effective complete response rates for CT + radiotherapy in patients Tyvyt is an IgG4 mAb, which helps in binding with PD-1 in T cells further blocking PD-L1. In 2015, Innovent Biologics and Eli Lilly collaborated to […]Read More